Fueling the Seed: Growth Factors and Cytokines Driving Cancer Stem Cells in Gynecological Malignancies
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms262311462 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Alessandro Sarcinella und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Sciences, University of Turin, 10126 Turin, Italy. Hauptthemen laut MEDLINE: Neoplastic Stem Cells, Cytokines, Genital Neoplasms, Female, Intercellular Signaling Peptides and Proteins. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 252 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Miur.
Abstract (Originalsprache)
Gynecological cancers remain a major global health burden due to their high incidence, molecular heterogeneity, and frequent resistance to conventional therapies. Beyond well-established genetic alterations and targeted treatments, growing attention has been directed toward the role of cancer stem cells (CSCs), a rare tumor subpopulation with self-renewal, differentiation, and tumor-initiating capacities. CSCs are sustained by a specialized microenvironment, the cancer stem cell niche, where growth factors, cytokines, hypoxia, and stromal interactions converge to promote stemness, chemoresistance, and metastatic potential. In breast cancer, signaling axes such as EGFR, IGF, TGFβ, and HGF/c-Met critically regulate CSC expansion, particularly in aggressive subtypes like triple-negative tumors. In ovarian cancer, factors including HGF, VEGFA, IGF, and stromal-derived BMPs drive CSC plasticity and contribute to relapse after platinum therapy. Endometrial CSCs are supported by pathways involving TGFβ, BMP2, and Netrin-4/c-Myc signaling, while in cervical cancer, VEGF, IGF-1, Gremlin-1, and TGFβ-mediated circuits enhance stem-like phenotypes and drug resistance. Cytokine-driven inflammation, especially via IL-3, IL-6, IL-8, IL-10, and CCL5, further fosters CSC survival and immune evasion across gynecologic malignancies. Preclinical studies demonstrate that targeting growth factors and cytokine signaling, through monoclonal antibodies, receptor inhibitors, small molecules, or cytokine modulation, can reduce CSC frequency, restore chemosensitivity, and enhance immunotherapy efficacy. This review highlights the interplay between CSCs, growth factors, and cytokines as central to tumor progression and relapses, emphasizing their translational potential as therapeutic targets in precision oncology for gynecological cancers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Sciences, University of Turin, 10126 Turin, Italy.
ORCID-Profile: Alessandro Sarcinella, Juan Sebastian Guerra Villacis, Maria Felice Brizzi
Förderung
- Miur
Zitieren
APA
Sarcinella, A., Guerra Villacis, J. S., & Brizzi, M. F. (2025). Fueling the Seed: Growth Factors and Cytokines Driving Cancer Stem Cells in Gynecological Malignancies. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms262311462
Vancouver
Sarcinella A, Guerra Villacis JS, Brizzi MF. Fueling the Seed: Growth Factors and Cytokines Driving Cancer Stem Cells in Gynecological Malignancies. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms262311462
BibTeX
@article{Sarcinella2025,
author = {Sarcinella, Alessandro and Guerra Villacis, Juan Sebastian and Brizzi, Maria Felice},
title = {Fueling the Seed: Growth Factors and Cytokines Driving Cancer Stem Cells in Gynecological Malignancies},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms262311462}
}
EUVIMED